Posted on Leave a comment

99% of Those Who Died From Virus Had Other Illness, Italy Says

corona virus

More than 99% of Italy’s coronavirus fatalities were people who suffered from previous medical conditions, according to a study by the country’s national health authority.

After deaths from the virus reached more than 2,500, with a 150% increase in the past week, health authorities have been combing through data to provide clues to help combat the spread of the disease.

Share this:

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

Prime Minister Giuseppe Conte’s government is evaluating whether to extend a nationwide lockdown beyond the beginning of April, daily La Stampa reported Wednesday. Italy has more than 31,500 confirmed cases of the illness.

Italy Coronavirus Deaths

By prior illnesses (%)

Source: ISS Italy National Health Institute, March 17 sample

The new study could provide insight into why Italy’s death rate, at about 8% of total infected people, is higher than in other countries.

The Rome-based institute has examined medical records of about 18% of the country’s coronavirus fatalities, finding that just three victims, or 0.8% of the total, had no previous pathology. Almost half of the victims suffered from at least three prior illnesses and about a fourth had either one or two previous conditions.

Threat to the Elderly

The median age of the infected is 63 but most of those who die are older
The average age of those who’ve died from the virus in Italy is 79.5. As of March 17, 17 people under 50 had died from the disease. All of Italy’s victims under 40 have been males with serious existing medical conditions.

While data released Tuesday point to a slowdown in the increase of cases, with a 12.6% rise, a separate study shows Italy could be underestimating the real number of cases by testing only patients presenting symptoms.

According to the GIMBE Foundation, about 100,000 Italians have contracted the virus, daily Il Sole 24 Ore reported. That would bring back the country’s death rate closer to the global average of about 2%.

Threat to the Elderly


Circularity is already in Phase 3 human clinical trials with most of the top ten U.S. university research institutions with D’OXYVA for FDA approval for rapidly treating chronic conditions such as diabetic wounds and hypertension, and fighting against COVID-19 with an already FDA-approved simple, non-toxic, and widely used molecule in nearly all hospitals around the world.

D’OXYVA is the only fully noninvasive, completely painless over-the-skin microcirculatory and nerve stimulant solution that has been validated to significantly improve microcirculation.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

5 Preexisting Conditions That Can Make It Harder to Fight Coronavirus

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.

Early data from China, where the new coronavirus COVID-19 first started, shows that some people are at higher risk of serious health complications from the new coronavirus. Per the Centers for Disease Control and Prevention (CDC), this includes people who have serious chronic medical conditions like heart disease, diabetes, lung disease, and mental health conditions such as depression and anxiety. 

That is why it can be a relief to discover an application that can be used for multiple health disorders that will help you save more money and that can be used at the comfort of your home just like with D’OXYVA application.

Share this:

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

Here’s why the following conditions increase the risk for COVID-19 complications—and what you should do if you’re affected.

People with heart disease tend to have other underlying conditions like high blood pressure, elevated cholesterol, diabetes, and lung disease, which weaken the body’s health defense systems (including the immune system) against a viral infection, William Li, MD, physician scientist and author of Eat To Beat Disease: The New Science of How Your Body Can Heal Itself, tells Health. 

“The fever associated with COVID-19 puts additional strain on the body’s metabolic demands, stressing out the already weakened heart,” explains Dr. Li. “Pneumonia, which is commonly seen with COVID-19, makes it harder for the lungs to oxygenate the blood. This puts further stress on the heart.” Plus, inflammation caused by the infection can damage the lining of blood vessels through which the heart pumps blood.

In February, the American College of Cardiology issued a bulletin to warn patients about the potential increased risk of COVID-19 that included additional precautions to take. The bulletin recommends that people with cardiovascular disease stay up to date with vaccinations, including for pneumonia, and get a flu shot to prevent another source of fever.

Dr. Li advises regular exercise (while social distancing, of course) and a healthy diet to help strengthen the heart during the COVID-19 era.

Chronic respiratory diseases (CRDs), which include asthma and pulmonary hypertension, are diseases of the airways and other parts of the lung. People with CRDs need to be especially vigilant about the coronavirus because one of the possible complications is pneumonia. “Pneumonia compromises the lung, which brings oxygen to the body,” explains Dr. Li. “In patients who already have a chronic respiratory disease, it can be lethal.”

Besides following the CDC guidelines for handwashing, social distancing, and other coronavirus preventive steps, The COPD Foundation has issued further advice for people with chronic obstructive pulmonary disease (such as chronic bronchitis or emphysema). As reported in Pulmonary Advisor, this includes having at least a 30-day supply of all required medications on hand. If a patient requires an oxygen supply, they should contact their supplier to find out how to prepare for a COVID-19 outbreak in their area.

Last week, actor Tom Hanks revealed on Instagram that he and his wife, Rita Wilson, tested positive for COVID-19. Hanks previously shared that he has type 2 diabetes, which means he’s at an increased risk of serious illness from the new coronavirus.

What makes the coronavirus so dangerous for people with diabetes? First, because the immune system is compromised, it’s harder for the body to fight off the coronavirus, states the International Diabetes Foundation (IDF). Viruses also may thrive when blood glucose levels are high.

People with diabetes have heightened levels of inflammation throughout their bodies, which is another risk factor. “If you have a viral infection, that can turn into pneumonia easier, because diabetes itself is an inflammatory disease,” Maria Pena, MD, director of endocrine services at Mount Sinai Doctors Forest Hills, previously told Health. “It’s also important to note that when a person has diabetes, episodes of stress, like a viral infection, can increase blood sugar levels, which can also lead to complications.”

Everyone should be taking precautionary measures during the COVID-19 outbreak (whether they have preexisting health conditions or not), and the IDF says it’s even more crucial for those living with diabetes. That means washing your hands thoroughly and frequently, avoiding touching your face as much as possible, cleaning and disinfecting frequently touched surfaces, and avoiding close contact with those showing symptoms of a respiratory illness.

The IDF also recommends additional precautionary steps for those with diabetes. Monitoring blood glucose levels should be a priority, because any kind of infection can raise blood sugar levels. This increases the need for water, so it’s important to have an adequate supply. To prepare for a quarantine, make sure you have enough medication, testing supplies, and food to last for at least a month.

People with diabetes should be particularly careful about social contact. “As a diabetic, I would avoid supermarkets or other public gatherings,” Dr. Pena said.

COVID-19 doesn’t only affect people with pre-existing physical conditions—it can have a serious impact on those with mental health issues, like anxiety and depression, even if you are not infected with the coronavirus.

“Fear of the virus and all the changes it’s causing are driving anxiety levels up for everyone, but for people who have an anxiety disorder it’s so much worse,” Gail Saltz, MD, associate professor of psychiatry at the NY Presbyterian Hospital Weill-Cornell School of medicine and host of the upcoming Personology podcast from iHeartRadio, tells Health. Dr. Saltz warns that people who have managed their disorder may relapse, and those actively struggling may be much more symptomatic.

“Anxiety also worsens depression, particularly those whose depression is of the ‘agitated’ variety, a subtype of the illness characterized by jittery, anxious, irritable behavior,” she adds.

People with anxiety or depression who are at home with someone who has COVID-19 may find the burden of caregiving to cause their mental health to deteriorate further. “Caregiving is very stressful,” says Dr. Saltz. “In many cases it’s a 24/7 role and for those already struggling, it can be overwhelming.” She adds that social distancing, quarantining, and losing the structure of work or school can also increase symptoms of both anxiety and depression by increasing feelings of loneliness.

By actively focusing on mental health, however, those symptoms can be reduced. Dr. Saltz recommends exercising for 30 minutes each day and trying relaxation techniques like deep breathing and mindfulness to help keep anxiety at bay.

It’s also important to have structure in your day, even if you’re self-isolating or in quarantine, she says. This means getting up at the same time as you normally would, taking a shower, getting dressed, creating and sticking to a schedule, and maintaining normal sleep. If you work from home, make a dedicated workstation.

If you need professional help, it’s still there for you even if you can’t get to the doctor’s office. “Most therapists are moving to online sessions to accommodate their patients,” says Dr. Saltz. If you take medication for your mental health, make sure you have a 30-day supply.

Loneliness is an issue for people in all age groups, and even if you don’t have mental health issues yourself, you probably know someone who does. “Check in with those you know who are also self-isolating,” says Dr. Saltz says. “Talking to and supporting others is likely to make you feel better as well.”


D’OXYVA is the only fully noninvasive, completely painless over-the-skin microcirculatory and nerve stimulant solution that has been validated to significantly improve microcirculation.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Doesn’t Your Health Deserve D’OXYVA?

        BUY D’OXYVA

Posted on Leave a comment

Non-Invasive Treatments: What No One Is Talking About

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.

Sometimes it seems like the best way to guess a person’s age is by how much medicine they take daily. This system is not perfect, as some people start medications early in life, but we all seem to accumulate pills and creams as we age. That is why it can be a relief to discover an application that can be used for multiple health disorders.

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

Alexa, a 58-year-old woman from Texas, United States, has suffered from type 2 diabetes for more than 6 years. She has been taking multiple medications and treatments such as inhibitors, metformin, pain relievers and antibiotics for her diabetic foot wound. After discovering D’OXYVA, a non-invasive application that significantly helped with her pain and wound management after 5 weeks of twice-daily application, she shared that she saved so much when she started decreasing the intake of other medications and avoided a possible amputation just by using this non-invasive application.

D’OXYVA, for example, can be applied for a variety of conditions related to poor circulation. This multi-application product helps consumers save money, space, and time while simplifying everyday life.

Here are a few things about non-invasive treatments that people seem unwilling to discuss.

In layman’s terms, non-invasive treatments do not break the skin or enter beyond the surface of body openings. Invasive treatments include surgery and injections. Because the needles actually penetrate the skin, acupuncture is also considered an invasive procedure. Certain procedures may be considered minimally invasive if they do not penetrate deeply into the body or only require a small incision.

Non-invasive procedures include massage and gas delivery systems such as D’OXYVA.

By nature, an invasive procedure can be hazardous. Even under a doctor’s care, for example, minimally invasive surgical procedures carry risks (Mayo Clinic). Patients can experience unforeseen complications related to anesthesia, infections, or bleeding. While these risks are mitigated with less serious regular treatments, any invasive procedure carries the potential for infections or bleeding complications.

While you should always trust your medical professional’s advice, many non-invasive treatments can be safer. Most doctors will attempt to find the least invasive, most effective treatment.

Although the human body contains many different cells and functional systems, most of them share the same basic processes. For example, every cell in the body depends on a healthy circulation system to receive nutrients and oxygen. Therefore, when a person has circulation problems, it can manifest as a number of issues. Your doctor may be able to recommend one product like D’OXYVA for multiple circulation-related issues.

Examples of Circulation Related Issues

  • Slow-healing wounds, especially those related to diabetes or other cardiovascular issues
  • Septic shock related to a severe infection or a compromised immune system
  • Many forms of chronic pain
  • Varicose veins and other blemishes


D’OXYVA is the only fully noninvasive, completely painless over-the-skin microcirculatory and nerve stimulant solution that has been validated to significantly improve microcirculation.The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

If you suffer from symptoms related to poor circulation, end your suffering in silence now!

        BUY D’OXYVA

Posted on Leave a comment

Is Active-Aging the New Frontier for Healthcare Technology?

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.

The number of Americans over age 60 is predicted to double by 2060 – bringing the total retirement-age population to 98 million people. The swell in this patient demographic has several implications for care delivery methods and the allocation of healthcare funds.

Share It

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

Elderly patients are more likely to grapple with chronic illnesses like diabetes and receive long-term care in senior living communities or in hospices. Additionally, older patients – whether receiving care at home or in facilities – often struggle with depression and loneliness. New technologies in the field of active aging can help negate these emotions and improve quality of life.

We may be tempted to brush off elderly patient populations as inept at technology, but we shouldn’t be so quick to underestimate them. Americans aged 50 and older generate roughly $7.6 trillion annually in economic activity, and will only continue to grow. To capitalize on this expanding market, the “active-aging” industry has emerged. This market includes patient safety and smart technologies, as well as remote monitoring and fitness devices – and is expected to be worth $30 billion by 2022.

Healthcare technologies for older Americans

Proactively engaging older Americans in their own health and wellness through technology is one way to improve longevity and quality of life while allowing this population to remain independent and active as they age.

Remote monitoring devices

Remote monitoring devices are one of the most obvious high-profile solutions for tracking and improving the health and safety of geriatric patients. These technologies include a variety of healthcare devices – like wearables, glucose monitors, and pacemaker implants – that can be controlled through smartphone apps and send data directly to care providers.

Smart watches can empower elderly patients to set medication alerts and stay active. These devices also provide location-tracking capabilities for patients living with Alzheimer’s. While FitBit and Apple devices garner most of the spotlight—particularly when it comes to fitness tracking—there are a variety of applications for this type of technology.

Nectarine, for example, is a smart wristband that aims to improve care for geriatric patients. The wristband monitors everything from a wearer’s sleeping and eating patterns to detecting motion changes that may indicate a trip or fall and can notify a specified caregiver of changes in behavior patterns or in an emergency.

No area is off-limits for remote monitoring technologies – even the bathroom. Toi Labs is currently running clinical trials of TrueLoo toilet seats in senior living communities. These digital toilet seats contain sensors that detect who the user is, and scans waste to detect dehydration, urinary tract infections (UTIs), irritable bowel syndrome (IBS), C. diff, and other gastrointestinal and urinary issues.

Automated devices like these allow patients and providers to access real-time health information and stay ahead of potentially life-threatening changes in heart rate or blood sugar. These tools are particularly helpful for older Americans living alone, who may not have immediate access to assistance in an emergency.

Medical device market share by vendor installs


Fig 1 Image taken from the DHC Visuals LOGIC platform within Definitive Healthcare’s product suite. The chart features the top 10 most-installed medical devices by vendor. Data accessed on Jan. 7, 2020.

Medical device market share by product installs


Fig 2 Image taken from the DHC Visuals LOGIC platform within Definitive Healthcare’s product suite. The chart features the top 10 most-installed medical devices by product. Data accessed on Jan. 7, 2020.

Virtual reality

Virtual reality (VR) isn’t just for gaming anymore. Developers are using VR technology to help mitigate depression and feelings of isolation for geriatric patients living alone or in senior communities.

Specialists work with patients one-on-one or in groups, providing opportunities to relive positive experiences and make new connections with others living in the same community. VR programs like Rendever offer reminiscence therapy, which allows users to virtually revisit childhood homes and other important locations, and group experiences that let users digitally travel to locations all over the world.

Physical therapy treatments are also benefiting from VR technology. Neuro Rehab VR leverages machine-learning to customize activities and exercises to each patient’s recovery goals and current ability. This makes physical therapy more like a game, with trended scoring and metrics that encourage patient progress.

Smart home devices

Smart speakers and voice assistants like the Google Home and Amazon Echo have become more popular and widely accessible in recent years. These devices allow users to set timers, play music, control home lighting, and more – just by asking. Despite privacy concerns from skeptics, Americans continue to install smart speakers, video doorbells, smart thermostats, and other devices that make our lives easier by learning from our habits.

Elderly users and their caregivers can program smart speakers to set morning alarms and daily medication reminders, make phone calls to family members or emergency services – and respond to user questions (such as, “what’s today’s date?).

In 2018, the ElliQ from Intuition Robotics became the first social robot made specifically for older adults. The digital companion robot combines touch screen and voice assistant technologies that enable seniors to make video calls, set medication reminders, arrange appointments, and even play games.

Engaging elderly patients in healthcare

Older Americans are at a disadvantage when it comes to technology. Often, it is geared toward younger audiences that grew up with these devices or have had significant time to integrate them into daily life. To ensure that geriatric patients are able to use this technology effectively for personal health management, developers must create their devices with this audience in mind— with simple interfaces and clear instructions that require minimal training.


D’OXYVA is the only fully noninvasive, completely painless over-the-skin microcirculatory solution that has been validated to significantly improve microcirculation.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Posted on Leave a comment

Top 5 New Innovations in Health Care Technology To Watch Out On 2020

health technology innovation

The following are the top 5 new innovations in health care technology, some of which aided in the early lung cancer diagnosis of Amos B, a 58-year-old man who had been coughing up blood for 2 months. Amos was also experiencing loss of appetite, hoarseness, wheezing, and shortness of breath; he had smoked 2 packs of non-filtered cigarettes daily since he was 15 years old. 

Share It

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

Amos’ early lung cancer was diagnosed using artificial intelligence for the analysis of his lung CT and of lung biopsy samples. He received early treatment and recovered completely.

#1 – Artificial Intelligence for Use in the Pathological Diagnosis of Lung Cancer

Artificial intelligence (AI) refers to the performance of tasks by computers that normally would require the input of human intelligence.

Using AI, specialized pathology computer programs are able to diagnose lung cancer based on the recognition of abnormalities found on slides of pathological specimens of lung tissue[1].

To accomplish this, a computer program was programmed to read hundreds of pathological slides of lung tissue and recognize various forms of lung cancer with an accuracy rate even higher than that of pathologists.

#2 – 3D Printing for Use in Total Knee Replacements

Image result for 3D Printing for Use in Total Knee Replacements

3D printers, which were first developed in 1983, make 3-dimensional objects by laying down successive layers of material following a computer-aided design (CAD).

This specialized software uses the specific measurements of CT scans of the knee, hip, and ankle to make an exact 3D model of a patient’s knee.

When a knee replacement is produced by 3D printing, the layers of the knee replacement consist of ABS plastic, resin, stainless steel, gold, silver, titanium, ceramic, and gypsum.

This process has been used in over 100,000 complete knee replacements during 2019.

3D-printed knee replacement results in shorter hospital stays, decreased recovery times, decreased post-operative pain, increased post-operative range of motion, and a better overall custom fit.[2]

#3 – Shravya Shetty: Artificial Intelligence Used to Diagnose Lung Cancer by Chest CT

Shravya Shetty[3], the head researcher of a Google Health Team, has developed an artificial intelligence algorithm to accurately diagnose lung cancer by analyzing chest CT scans.

The AI algorithm follows a set of commands (algorithms) to analyze the chest CT and even “learns” as it reviews CT scans.

After being trained with 45,000 lung cancer patients’ chest CT scans fed into an AI program, the AI program picked up 5% more cases of lung cancer then a team of 6 board-certified radiologists.

It also had 11% fewer false positive readings.

#4 – Semma Therapeutics Implantable Device for Insulin Delivery

Semma Therapeutics[4], recently acquired by Vertex Pharmaceuticals, is in the process of developing an implantable device for type 1 diabetes (which occurs due to an autoimmune response that attacks the insulin-producing beta cells of the pancreas).

This implantable device contains a supply of pancreatic islet cells derived from high-quality human pluripotent stem cells.

These stem-cell derived pancreatic cells have been found to produce almost normal levels of insulin and successfully lower blood sugar levels.

The insulin is released through the membrane of the device, which is permeable to insulin and glucose but not to immune cells.

This keeps immune cells out of the device, thus avoiding immune reactions such as organ rejection.

#5 – D’OXYVA Deoxyhemoglobin Peripheral Vasodilator

D’OXYVA[5] is an innovative, painless, non-invasive, deoxyhemoglobin vasodilator application that works by applying a transdermal vapor of CO2 and water through the skin of the thumb over a 5-minute period.

The CO2 then travels to the microcirculation system (smallest blood vessels in the body: arterioles, venules, and capillaries), where it stimulates vasodilation.

This vasodilation of the microcirculation system increases the amount of oxygen and nutrients delivered to the tissues, which results in various healing effects.

D’OXYVA, which is produced by Circularity Healthcare, has been used with great application success in non-healing diabetic foot ulcers, chronic wounds, chronic pain, depression, poor athletic performance, cardiovascular rehabilitation, migraine headaches, diabetic neuropathy, varicose and spider veins, and other conditions.


D’OXYVA is the only fully noninvasive, completely painless over-the-skin microcirculatory solution that has been validated to significantly improve microcirculation.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Posted on Leave a comment

Wearable technology named top health and fitness trend for 2020

health and fitness trend for 2020

More Americans are using wearable fitness trackers than ever to monitor their health, a trend the American College of Sports Medicine says is the top fitness trend for 2020, according to a recent survey.

ACSM’s “Worldwide Survey of Fitness Trends for 2020” interviewed over 3,000 health and fitness professionals, all of which said that wearable technology will be the top trend in fitness next year, with millions of Americans already using such technology to monitor their exercises, heart rate, calorie consumption, sleep quality and step count.

“Wearable tech has become ingrained in today’s culture, and the industry shows no signs of slowing down,” said Walter R. Thompson, Ph.D., ACSM Past President and lead author of the survey and associate dean in the College of Education and Human Development at Georgia State University in Atlanta. “Tech advances have made it easier than ever for users to collect important health metrics and work with fitness professionals and health care providers to improve exercise efficiency, develop healthy lifestyles, manage chronic diseases and, ultimately, increase quality of life.”

This year, ACSM published a new article alongside the survey, “Regional Comparisons: The Worldwide Survey of Fitness Trends,” which compared the top 20 fitness and health-related trends in North America, South America, Europe and China in an effort to gain a better understanding of global developments throughout different regions worldwide. The same methodology was used by ACSM’s “Worldwide Survey of Fitness Trends” in tracking these global trends.

“Through the regional comparison we hope to enhance the scope, reach and relevance of the ACSM fitness trends survey to truly make it an international collaboration,” said Vanessa M. Kercher, Ph.D., M.Ed., co-author of the regional comparison article and a clinical assistant professor in the school of public health at Indiana University. “We plan to continue developing our international partnerships with the goal of improving and expanding the implementation and methodology of the ACSM fitness trends survey. By doing so, we aim to identify fitness trends specific to different international regions so we can explore and communicate regional similarities and differences to readers.”

Wearable fitness devices are expected to evolve quite a bit in the coming years, with Apple patenting  “smart clothes” technology last year that can measure heart rate, blood sugar levels, blood pressure, electrocardiograms, blood oxygen levels and respiration rates all through sensors woven into clothing fabric.


Is your wearable really fitness technology or just more of a fad? If your wearable records heart rate, blood pressure, blood sugar, blood flow (perfusion index), blood oxygen (SpO2), blood pH, we challenge you to prove that you have the best wearable by testing its efficiency with D’OXYVA.

D’OXYVA is the only fully noninvasive, completely painless transdermal (over-the-skin) microcirculatory solution that has been clinically tested to significantly improve microcirculation.

Results of improved blood flow (perfusion index) is visible in just after 5 minutes of D’OXYVA therapy and on its highest just after 30 minutes!

Are you up for the challenge? Register below to get further details! Amazing prizes await!

Posted on Leave a comment

Mental health crisis hotline launched in the Philippines

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.

Amid the rising suicide prevalence in the country, the Department of Health (DOH) yesterday launched a mental health crisis hotline aimed at helping curb the problem.

Health Secretary Francisco Duque III said the National Center for Mental Health (NCMH) crisis hotline will operate 24/7 to provide counseling for those at risk of committing suicide and other people suffering from mental health conditions.

The new NCMH crisis hotline can be reached at 0917-899 8727 or 989-8727.

“Everyone is enjoined to support the dissemination of the hotline numbers,” Duque said as he noted the many lives that can be saved with the use of the hotline.

Duque said mental illness is a major public health concern in the country, with many patients reluctant to seek medical treatment due to stigma.

He said without the proper necessary intervention, many of those who are suffering from mental conditions take their own lives.

Data showed that 3.2 percent of every country’s population is likely to commit suicide.

Studies indicated that suicide is the second leading cause of death among people aged 29 to 59 years old worldwide.

The Goulbourn Foundation, which also operates a 24-hour suicide prevention hotline in coordination with the DOH, reported that three young people committed suicide last week.

The foundation said the youngest suicide victim they have recorded was a seven-year-old child.

There is still no available data on the national prevalence of mental illness in the Philippines, but the DOH said a study is underway to determine the extent of the problem.

Duque said records from the NCMH showed the government-run institution has an average of 7,500 in-patients and serves up to 65,000 outpatients annually.

“The NCMH figure could be an indicator of the gravity of mental health problem in the country,” he said.

Duque expressed optimism that the health problem could be addressed with the implementation of the Mental Health Act.

He said the law mandates the DOH to develop a national suicide prevention strategy, which now includes the establishment of the NCMH crisis hotline.

NCMH officer-in-charge Allan Troy Baquir said the hotline would help people who are experiencing anxiety and depression as well as health workers who need guidance in handling their patients with mental illness.

Operating on a P7-million budget, the hotline will assess the needs of the callers and refer them to proper specialist or medical facilities if necessary.

Also yesterday, the DOH launched programs under the Kalusugan at Nutrisyon ng Mag-Nanay Act.

The new program aims to boost children’s health and reduce stunting and malnutrition.

Duque said the DOH would provide pregnancy and after birth medical services to both mothers and infants.


D’OXYVA is the only fully noninvasive, completely painless transdermal (over-the-skin) microcirculatory solution that has been clinically tested to significantly improve microcirculation.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Posted on Leave a comment

Trump Ready To Force Transparency In Healthcare Pricing With An Executive Order

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.

The Trump Administration wants to make it easier for patients and employers to comparison shop for healthcare. On transparency, one can’t fault the Administration for not trying.

So far, the measures implemented have mostly been baby steps. But, this is about to change as President Trump is expected to soon release an executive order on healthcare price transparency. If enacted, this executive order would mandate disclosure of prices throughout the healthcare industry, and be enforceable by federal agencies. It would provide patients and employers pricing data that reflect the negotiated rates between insurers, hospitals, and physicians.

In the lead-up to this week’s expected announcement on the executive order, the Trump Administration has been gradually chipping away to uncover the murky world of healthcare pricing. For example, in October 2018, President Trump signed two bills into law, the Know the Lowest Price Act and the Patients’ Right to Know Drug Prices Act. These bills removed pharmacy gag clauses, imposed by pharmacy benefit managers, which had prevented pharmacists from proactively telling consumers if their prescription would cost less if they paid for it out-of-pocket rather than using their insurance plan.

And, this month, the Department of Health and Human Services (HHS) announced that direct-to-consumer (DTC) advertisements of prescription drugs on television will soon be required to include price information.

Nonetheless, the pharmacy gag clause bills and requirement to include list price information in DTC advertisements only incrementally address prescription drug price transparency. A much bigger step would be to overhaul the prescription drug rebate system, as proposed by HHS. However, it’s unclear whether and when that will happen.

Ultimately, drug price transparency alone won’t be sufficient to create conditions conducive to a competitive market. It needs to be coupled with dissemination of information on which medications are the most effective for specific conditions or diseases. There have been a number of efforts in the commercial sector to address this issue; MedSavvy, for example, which is a Cambia Health Solutions company. Regence Blue Cross and Blue Shield offers MedSavvy to its customers. The federal government is also supporting initiatives to improve the Patient-Centered Outcomes Research Institute’s publication of usable information on comparative effectiveness to consumers. But it’s been a very slow process with few tangible results thus far.

The Trump Administration has also focused on disseminating information regarding the quality of physician practices that serve Medicare beneficiaries. The Centers for Medicare and Medicaid Services (CMS) established a website called Physician Compare. However, nearly 80% of physicians aren’t included in the website database. Reporting is voluntary, and so there’s selection bias when it comes to the performance data that do appear. Moreover, the website doesn’t include a comparison of fees for physician services.

Beginning January 1st this year, the federal government is requiring every hospital in the U.S. to post lists of prices of services and technologies online. Such lists are known in the industry as “chargemasters” that comprise of prices of thousands of services and products for which a hospital may bill.

But, CMS acknowledges it is not yet enforcing the hospital pricing rule. Furthermore, implementation of the rules has sparked a debate about whether the price lists are creating more confusion than clarity among patients. Services and products are identified in acronyms, abbreviations, billing codes, and medical terminology that most consumers can’t be expected to understand.

Additionally, the chargemaster lists don’t normally reflect actual transaction charges because hospitals and insurers generally negotiate significantly lower prices. And, hospitals and insurers are resisting public disclosure of negotiated prices. This week’s expected announcement of an executive order may make such resistance a moot point.

Most patients don’t comparison shop for medical care. Some might not be in a position to do so. Others may simply balk. Perhaps this is due in large part to patients not being used to comparison shopping, or to the opaque character of pricing in the healthcare system. As more useful information becomes available, perhaps patients will begin to do more comparison shopping. which in turn will lead to a more competitive market.


D’OXYVA is the only affordable, fully noninvasive, completely painless transdermal (over-the-skin) microcirculatory solution that has been clinically tested to significantly improve microcirculation.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Posted on Leave a comment

Too Many Medicines Simply Don’t Work

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.

It’s possible that the medicine you’re taking isn’t helping—even if it’s been approved by the Food and Drug Administration. That’s the upshot of a pair of studies in the latest issue of JAMA Internal Medicine. Not good. As an invited commentary in the same issue says, “Charging vulnerable patients for drugs without evidence that they actually improve patients’ survival and quality of life is unconscionable.”

One study examines 93 cancer drug uses that were granted accelerated approval by the FDA between 1992 and 2017. Of those, only 19 showed improvement in overall survival. Another 39 showed improvement by a surrogate measure, such as tumor shrinkage. The problem with surrogates is that they aren’t always accurate measures—drugs that shrink tumors don’t necessarily make people live longer. Some of the other drug uses that got accelerated approval were still in a gray area as of 2017 because their confirmatory trials were delayed, pending, or ongoing. Five of the 93 were withdrawn or had their approvals revoked.

The second study in the journal zeroed in on cases where the FDA approves drugs based on the response rate—the percentage of patients whose tumors shrink by a certain amount. It found that the threshold for approval can be quite low. Of 85 cancer drug uses approved on the basis of response rate, 40 shrank tumors by less than 40 percent. The authors suggest that some of the drugs could be tested before they hit the market by “measuring directly end points that demonstrate clinical benefit,” not just tumor shrinkage.

To be fair to the FDA, it’s under intense pressure to accelerate approval of drugs that appear to have the potential to save lives. In an email, FDA spokeswoman Amanda Turney wrote, “The FDA only approves drugs when the data received in a drug application demonstrate a favorable risk-benefit profile. Patients with refractory diseases often have few or no therapeutic options and we take that into account when examining the risk-benefit profile of these drugs.” (A refractory disease is one that doesn’t respond to conventional treatments.) Turney’s email also says that survival rate isn’t the only valid endpoint to consider when deciding whether to approve a drug.

But the invited commentary by Dr. Ezekiel Emanuel of the University of Pennsylvania’s Perelman School of Medicine and two co-authors says that the FDA is leaning too far toward approving drugs without proven efficacy. It cites for example the FDA’s approval of bevacizumab for progressive glioblastoma, an aggressive brain cancer. According to the commentary, “the confirmatory trial, with more than 400 patients, reported no improvement in terms of overall survival, quality-of-life end points, or neurocognitive functioning.” What’s more, almost two-thirds of the patients on bevacizumab had severe to life-threatening side effects.

“Drugs with unproven effectiveness sell false hope to desperate patients, who are likely paying thousands of dollars out of pocket for them,” the commentary says. “Private insurance companies, Medicare, and Medicaid pay millions—maybe billions—of dollars for drugs for which we do not know the real benefits and risks. This raises insurance premiums and wastes tax dollars.”

By coincidence I just finished reading a book on this theme, published in 2015, called Ending Medical Reversal: Improving Outcomes, Saving Lives, by Dr. Vinayak Prasad of Oregon Health and Science University and Dr. Adam Cifu of the University of Chicago. Prasad was the lead author on the response rate paper in the latest JAMA Internal Medicine.

Ending Medical Reversal argues that drugs, surgeries, and other treatments shouldn’t be approved without proof of their value from the gold standard of evidence: randomized controlled trials. In such trials, some patients are randomly chosen to get the treatment while the others get a placebo. A placebo isn’t always a sugar pill; it can be a sham surgery that looks and feels to the patient like the real thing.

The book’s appendix features 146 medical interventions that were once accepted practice but were ultimately reversed. Estrogen replacement for postmenopausal women and stents for stable coronary-artery disease are two. Another example from the introduction: “In one decade, doctors recommend an aggressive treatment of high-dose chemotherapy and stem-cell transplantation for women with breast cancer, promising that it will give a woman her best chance of a cure. Then, over the next decade, doctors report that all of that enthusiasm was misguided; the aggressive treatment was no better than a less aggressive course of therapy, which, incidentally, was what we had been doing previously.”

For another perspective on accelerated drug approval, the FDA referred me to Dr. Brian Druker, an oncologist at Oregon Health and Science University who helped develop Gleevec for treatment of chronic myeloid leukemia. (The costly compound was patented before it reached his lab so he never earned royalties.) Druker said it would be a mistake to end the FDA’s accelerated approval process. Drugs that may not work for everybody could still be lifesavers for certain diseases and certain populations, he said.

Still, Druker says the JAMA Internal Medicine papers raise important points. “It becomes a really difficult debate,” Druker says, “but one that’s worth having.”


D’OXYVA is the only fully noninvasive, completely painless transdermal (over-the-skin) microcirculatory solution that has been clinically tested to significantly improve microcirculation with consistent measurable benefits.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.

Posted on Leave a comment

Analysis: Has Trump actually done anything about drug prices?

D'OXYVA | Cardiovascular, Diabetes Care, Pain Reliever in CA.

Did you know the annual average cost of insulin per diabetic is about $6,000 and the monthly dosing of the 10 most advertised drugs is between about $500 and $17,000 in the States? Have you considered D’OXYVA’s immediate and significant benefits and advantages?

The administration has turned public anger at the pharmaceutical industry into real action — but has also left many meaningful opportunities on the table.

Donald Trump’s promise of sweeping health-care reform has not come to pass. While the president campaigned heavily on assurances to “repeal and replace Obamacare” on “day one” with an unspecified plan for every American to have affordable health care, his claims have now been diluted to a focus on “drug prices.”

One of his first comments on the release of the Mueller report was that it was a distraction from the need to “get back to infrastructure, get back to cutting taxes, get back to lowering prescription drug prices.”

Trump’s calls to action have been interspersed with claims of victory. In March of last year, Trump promised, “You’ll be seeing drug prices falling very substantially in the not-too-distant future, and it’s going to be beautiful.” Just 10 months later, in his 2019 State of the Union address, this had ostensibly already happened: “As a result of my administration’s efforts, in 2018 drug prices experienced their single largest decline in 46 years.”

Drug prices are still increasing. While growth in spending on drugs has slowed in recent years, total national spending continues to grow. Americans spend more than anyone else in the world. The average person spends $1,025 per year on medication — an inflation-adjusted increase of elevenfold since 1960.

Still, the cost of drugs accounts for only about 10 percent of the country’s health expenditures, and this trend has been steady for almost two decades. Exorbitant as drug prices are, a relatively small 24 percent of people say they have any “difficulty affording medications.” It is medical bills that cause much more angst and financial hardship, and are now the leading cause of bankruptcy in the United States. Slowing the growth of pharmaceutical costs would put only a small dent in the much bigger problem.

The focus on drug pricing is also curious as an ideological outlier for Trump. Among goals that have included protecting the fossil-fuel industryderegulating big banks, and handing out corporate tax cuts, the president could be expected to celebrate the $1.1 trillion pharmaceutical sector and the many jobs it provides. Instead, at least rhetorically, here he has chosen to side with consumers.

So what has Trump actually done about drug prices?

Last year, the administration did indeed lay out some proposals in a “blueprint’’ that included a long list of niche policy bullet points. Most notable among them were efforts at transparency and simplification: eliminating some rebates paid out by drug companies that obscure the price of drugs, using international comparisons for pricing Medicare drugs, and requiring drug companies to include prices in advertising.

It would be difficult to attribute any recent changes in drug prices to these measures, though, because they have not actually taken effect yet.

In the past two weeks, the issue started to come to a boil. The Congressional Budget Office projected that limiting rebates would not result in lower list prices, and would actually increase federal spending on drugs over the next decade by $170 billion. In the wake of that setback, the administration forged ahead with an announcement on Wednesday that the requirement to disclose drug prices in TV commercials would be implemented in July.

This may be the most noticeable single move the administration has made on the issue. In its news release, the Department of Health and Human Services cites the fact that the 10 most commonly advertised drugs have list prices ranging from $488 to $16,938 per month or course of treatment. Sharing this number would hypothetically encourage companies to lower their prices. Though if the requisite two-minute listing of gruesome side effects didn’t render ads ineffective, a price tag might not either—especially when it’s not the price that most consumers end up paying.

Patchwork regulation of this sort has historically failed to contain the pharmaceutical industry, which has continued to find ways to pass costs on to consumers and remain, consistently, extremely profitable. This is in part because of a system in which several layers of middlemen and reimbursement schemes serve to keep costs hidden from both patients and doctors, and fully apart from most decision making. While the advertising-disclosure requirement is a move toward cultural consciousness of cost, it has traditionally been market competition that has led to real price decreases. At a time when Trump’s executive orders are projected to leave fewer people with comprehensive health insurance, gestures at price transparency are unlikely to render them able to afford drugs out of pocket. Though drug prices are a popular talking point, if the overall goal were actually keeping American people alive and well, it would require a systemic reform of the health-care system.

In contrast to the drugs, which are integral to our existence and the functioning of our bodies and our understanding of ourselves, the system by which we procure them is opaque and foreign to most people, even though everyone is constantly paying for drugs. Part of every American’s paycheck goes to Medicare, the largest buyer of drugs. And everyone is familiar with the drugstore itself, a sort of microcosm of the country’s drug-pricing problem.

Many of the largest pharmacy chains, such as Walgreens and CVS, explicitly brand themselves as bastions of health and/or wellness. Yet the pharmacy itself is always at the back of the store. Four of the top five most prescribed drugs in the U.S. are used to treat elements of metabolic syndrome — the constellation of high blood pressure, diabetes, and heart disease that is strongly tied to what we eat. But in order to get these medications, you have to walk past two aisles of candy (one seasonal). This is not to mention an onslaught of magazine covers of extremely thin, young people with eerily white teeth.

You can buy a whitening system for your teeth, too. And the coffee to stain them back. And the sleep aids to counteract the caffeine. If there is a unifying philosophy to drugstores, it is that they sell things that have a potential to produce profit. At the back of the store, the drugs that constitute some of the few products that are essential to life — such as insulin — are often not cheap. An annual supply of insulin in the U.S. costs more than any other country, around $6,000. What’s more, from 2012 to 2016, the price roughly doubled — a textbook case of the pharmaceutical industry inexplicably increasing prices.

Insulin was the subject of congressional hearings last month that included the three biggest makers: Sanofi, Eli Lilly, and Novo Nordisk. Pharmaceutical companies traditionally justify high prices based on the costs of developing new drugs. In the case of insulin, the innovation that would justify such costs is not obvious. These companies did not invent or reconceptualize insulin. Some changes have been made to how long various insulin formulations last in the body, but there has been no revolution; the drug is an analogue of the hormone produced in the pancreas, similar to the insulin that was taken initially from pigs and given to humans a century ago.

Just before the hearing, Sanofi and Eli Lilly announced they would lower insulin prices (for some patients). Representatives called them out for only acting once called out. Joseph Kennedy was exasperated at the fact that this happened only after “15 years of global outcry.”

The drug companies gave a new, karmic defense: that others were now unfairly profiting off of them. They blamed high consumer costs on rebates being paid to a new layer of middlemen known as pharmacy benefit managers (PBMs). The three dominant PBMs—Express Scripts, OptumRx, and CVS Health—were also present at the hearing, seated shoulder to shoulder with the pharmaceutical companies, with each industry blaming the other for high prices while in fact both were profiting. As a group, PBMs spent $1.5 millionin lobbying in the first quarter of this year, an all-time high. This is a fraction of the pharmaceutical industry’s $9.9 million spent in the same quarter. That very lobbying practice is a potential target to truly rein in drug costs that Trump has not pursued.

Whether or not the plan to ban some rebates comes to pass may matter little. Such rebates — which Secretary of Health and Human Services Alex Azar, a former Eli Lilly executive, has called “a hidden system of kickbacks to middlemen” — are already a shrinking part of PBM profits. As in most large industries, corporations often look seven or eight steps ahead of potential regulatory impediments and preemptively create new revenue streams. As the CBO report put it, prices would not come down for patients because, rather than lowering list prices, drug companies would negotiate with PBMs using an alternative process known as “chargebacks.”

Without getting too far into the details about how all this matters to those of us in line at the pharmacy, as we’re assaulted by some Bruno Mars song and forced to stare at Red Bull and discount Peeps, the semantics of drug pricing are important. Even the oft-repeated phrase drug prices is less straightforward than it seems. First, there’s a list price, which is like the sticker price on a car: traditionally not what most people actually expect to pay. (Though under the more and more common high-deductible plans supported by the Trump administration, more people are paying the full list price.) In many cases, insurers and PBMs negotiate prices that are radically different from the list price. A net price is what’s actually paid to pharmaceutical companies after rebates. The complexity is an element of the 10-dimensional chess that is not entirely unintentional, and serves to thwart attempts at price transparency.

Even drugstore receipts could serve as an imperfect analogy for the convoluted system of drug prices. If you’ve ever been to a CVS, you know that the receipts are accompanied by a scroll of coupons as long as a large dog. Sometimes there are coupons for $5 off any item — meaning a $5 bag of almonds is free. If you used all these coupons diligently, and then calculated prices accordingly, it could be difficult to get an accurate picture of costs and profits. Then imagine that the coupons were even more dramatic and numerous, and sometimes you got one that was $1,000. How would that affect the very idea of price?

Ultimately the most meaningful measurement of trends may be total national spending on prescription drugs, which has clearly increased. Though the rate of growth slowed in 2018, prices are simply not falling. The White House justified the president’s State of the Union claims by citing a 2018 report from its council of economic advisors, as well as data from the consumer price index for prescription drugs that showed a decline in list prices in January 2019 compared with the year prior. Without knowing how rebates changed—PBMs are notoriously secretive about this—it’s difficult to know what that means.

Even looking at list prices alone, more than 3,000 drugs went up, while only 117 went down. A report by the Associated Press found that 46 name-brand drugs decreased in price, but 4,412 increased. These sorts of analyses highlight the power of a few, intergalactically priced outliers — like the $700,000 hepatitis medication Sovaldi — to shift averages. The majority of drugs are considered “small molecule,” and in the generic market, which constitutes some 90 percent of drugs, people tend to take little issue with their prices.

Cholesterol-lowering statin medications, for example, are sometimes cited as how the market is “supposed” to work: A discovery is made, and a company takes in huge profits for a few years to reward the risk of investment in clinical trials. The artificial monopoly period ends after seven years, generic manufacturers move in and create identical products, and the price drops accordingly (in many cases). That process—a mix of free-market and governmental control—has made significant treatments available at reasonable costs to most Americans. Monopoly expirations have saved buyers about $65 billion over the past five years. The generic market accounts for an ever-greater percentage of prescriptions, and the Trump administration has made continued efforts to expand that.

The public perception that many or most drugs are maliciously overpriced comes largely from the minority of cases of brand-name drugs for which companies have consistently raised prices far beyond inflation — just because they can. Other wealthy countries have a system that reimburses drug companies based on the value of their product. The U.S. stands alone in allowing manufacturers to charge whatever they like. As in the yacht industry, this market-based approach gives producers an incentive to maximize profit, not to maximize the number of consumers.

To that end, the other potentially significant effort the Trump administration has made is a continuation of Barack Obama–era initiatives to accelerate the approval of generic drugs and increase competition among drugmakers. But there’s scant evidence yet that the approvals have had that effect. For unclear reasons, many of the generics haven’t actually gone to market.

Single-source issues sometimes plague the generic market, too, as with the lifesaving EpiPen’s overnight jump from $57 to $317. This is also where the now-incarcerated former pharmaceutical CEO Martin Shkreli (the “pharma bro”) caused havoc when he increased the price of a 50-year-old, lifesaving antibiotic for HIV patients several-thousand-fold overnight. These and other drugs should be cheap—they are off-patent and not expensive to produce. Fortunately, this kind of profiteering happens mostly at small scales. Rarely are abuses so egregious and ostentatious, and public ire so clearly directed at a single, unrepentant character.

Even still, Shkreli went to prison for securities fraud; the pricing itself was not illegal. Had he increased the price of the drug more quietly, and said with somber resolve that it was an unfortunately necessary move in order to be able to invest in future research and development, he would likely be a free man in the company of other extremely wealthy executives.

This is where Trump’s tough rhetoric may have had some effect on prices. When the president professes to hold drug companies accountable, even if it never comes to pass, they may be less likely to call attention to themselves with a spurious 400 percent price increase. Still, the Band-Aid approach is not satisfactory to those who insist on a fair, predictable, market-driven system. As Senator Chuck Grassley put it during the insulin hearing: “It shouldn’t take months of bad press, persistent public outcry, and increasing congressional scrutiny to get a company to charge a fair price. That’s not how a functioning marketplace works.”

Increasing generic competition, even sprinkled with public shaming, still leaves a growing hole in the regulatory framework around the newest way that pharmaceutical companies are making money: specialty medicines, or “orphan drugs,” with small potential markets but much greater potential for profit. For example, the FDA recently approved a $375,000drug to help treat a rare disorder called Lambert-Eaton myasthenic syndrome. A gene-therapy drug whose makers say it can cure spinal muscular atrophy is expected to hit the market soon at a cost of $2 million. Manufacturers justify these prices based on smaller markets and the fact that the drugs can sometimes have actual lifesaving value.

This space also includes drugs known as “biologics,” defined vaguely by the size and complexity of the molecule. Relative to traditional, small-molecule drugs, biologics are also more customized to specific consumer populations. Imagine an aisle at the pharmacy where your name is on the sign overhead, next to “juice.” Such specificity would be a marked change from the age-old business model for drugs where everyone lines up at identical, cookie-cutter drugstores to receive cookie-cutter drugs in slightly different doses and colors. More targeted drugs have smaller markets but a higher likelihood of helping any given person. Biologics constitute just 1 percent of the pharmaceutical market but have exploded to 30 percent of spending. This is in part because they enjoy an especially long artificial monopoly period of 12 years. If a person wanted to have a talking point about addressing drug prices, this could be a place to start.

Democrats in Congress have, drafting legislation that would decrease that period to seven years. Rather than embracing this bipartisan move, Trump has gone the opposite direction. His new iteration of NAFTA, the United States–Mexico–Canada Agreement, is protective of the pharmaceutical industry, forbidding Congress from shortening patent monopolies.

The tension that undermines any cohesive progress on drug prices is evident in Trump’s populist rhetoric, which swings between protecting and demonizing American pharmaceutical corporations. On a global scale, he depicts the industry as a victim. Domestically, it is ripping people off. As he put it in his State of the Union: “I am asking the Congress to pass legislation that finally takes on the problem of global freeloading, and delivers fairness and price transparency for American patients.”

The mention of freeloading is an apparent reference to the fact that pharmaceutical companies charge much lower prices in international markets. Though as Azar described in October, this is because the companies take advantage of Medicare’s inability to negotiate. Companies charge higher prices to the U.S. government because, frankly, they can. HHS has proposed implementing a pricing system that accords with international standards, but in Azar has also warned that this may simply cause drug companies to stop selling their products internationally rather than lowering their prices in the U.S.

As Trump briefly acknowledged, if the country really wanted to rein in the pharmaceutical industry, and to see more Americans provided with effective drugs at affordable prices, the approach would have to be systemic, not a patchwork of publicly shaming the worst abuses after they have occurred. It could mean asking who, really, is “freeloading.”

Sharing in the Shkreli outrage in 2015, Hillary Clinton laid out a plan to allow Medicare to negotiate lower drug prices. This was an initial component of Obamacare, too, that didn’t make it to law. The long-standing arrangement has been simply that a pharmaceutical company names its price, and then it has some 60 million potential consumers for whom the program (taxpayers) must pay that price. In the case of insulin, for example, Grassley questioned why the magnanimous price-lowering announcement did not include a discount for patients in federal programs. “If Sanofi can reduce the price to patients for insulin while still making a profit, I can’t imagine a legitimate reason taxpayers shouldn’t be charged the same price,” he said.

Allowing Medicare to negotiate prices with drug companies is an approach widely endorsed by Democrats and, historically, Republicans. It has bipartisan support of 92 percent among Americans. It was also endorsed in a recent report from the National Academies of Sciences, Engineering, and Medicine. The Trump administration made a partial gesture in this direction last year, announcing that it would allow Medicare Advantage plans (those paid for by the government but administered by private insurance companies) to negotiate prices with drug companies. But the administration has not pursued negotiation on behalf of the the much larger Medicare pool, despite Trump’s branding as an advocate of deal making. A bill allowing such negotiations was introduced by Democrats again in February but remains unheard.

Instead, in April, the Department of Commerce proposed limiting the government’s ability to take action against monopolies by removing an existing allowance for intervention in cases of exorbitant drug prices. It’s part of a 1980 law known as Bayh-Dole, which established the current system in which federally funded research institutions license discoveries to privatized pharmaceutical corporations, which then develop marketable products. Ownership of patents for drugs based on discoveries made using federal funds remains with the academic institutions, not the government. But the academy can exclusively license intellectual property rights to drug companies and get royalty payments. The grant funding is part of a $38 billion federal budget line for the National Institutes of Health. So in a sense, the public not only pays for the discovery on which new medicines are based, but also then pays for the resulting products at a price that the industry picks.

If Trump wanted to rally populist support around the problem of drug prices, he could call attention to the fact that tax dollars are used to develop drugs. They are then advertised under tax-exempt auspices in television commercials that pitch consumers directly, a practice that almost no other country permits. Then, it is tax dollars that go to buying the drugs from the corporations — with Medicare as the single largest purchaser. A profitable industry relying on a federal funding pipeline may not have been the vision of the senators who wrote the law, but one thing they did foresee was the potential for price gouging. The law includes a clause that gives the government “march-in rights” when a company using a taxpayer-funded discovery is not made available to the public “on reasonable terms.’’

In such cases — which have never actually happened — the government could override a patent and license someone else to market a drug. Though these rights have never been used, the potential for this intervention has served as a check on pharmaceutical companies. Some Democratic members of Congress wrote to Trump after he put the pharmaceutical industry on his list of targets in 2017, urging him to use this allowance to create specific guidelines as to what would constitute unreasonable terms, and what sorts of actions the government would take. But instead of acting on it, or even using it as a threat, the Trump administration is moving to eliminate it.

The overall effect of weighing what has actually been done with what could have been done leaves little hope that drug prices are indeed the priority Trump claims. The administration has made a series of reasonable gestures without meaningfully threatening the pharmaceutical industry, much less overhauling the health-care system. This sort of middle-ground approach to tinkering with the status quo is at odds with the burn-it-all-down ethos of the Trump campaign.

At the same time, the ongoing rise in support by some Democrats for single-payer health care — which in some models would eliminate private insurance companies altogether — could lead to the spread of such a philosophy to other highly profitable and widely disliked sectors. The presidential candidate Elizabeth Warren has introduced legislation that would let the government manufacture generic drugs. In some cases it could conceivably be less expensive for the government to pay the entire cost to develop a drug — from discovery through distribution — than to give monopolies to an industry that sells your discoveries back to you.

This shifting of the public-private partnership further toward the former would be at a far end of an ideological spectrum, where allowing Medicare to negotiate with drug companies is somewhere in the middle. In any approach, the overarching goal is to reward the sort of innovation that actually benefits the health of the population, as opposed to the innovation that optimizes the bottom line of each middleman profiting from taxpayer-funded innovations. Minimizing drug costs will ultimately be about tying reimbursement to value, rewarding innovation that meets consumer needs rather than keeping consumers in need. A market-driven approach will only work if companies have an incentive to treat diabetes rather than to sell as much insulin as is maximally profitable.

In some dream scenario, vendors of diabetes medications would even have some incentive not to also line their aisles with candy.


D’OXYVA is the only fully noninvasive, completely painless transdermal (over-the-skin) microcirculatory solution that has been clinically tested to significantly improve microcirculation.

The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits one’s health, immune system and overall sense of well-being in a variety of ways.